Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study

Trial Profile

Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Filgrastim (Primary) ; Mitoxantrone (Primary) ; Sorafenib (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Oct 2017 Planned number of patients changed from 77 to 71.
    • 12 Dec 2016 Status changed from not yet recruiting to recruiting.
    • 07 Sep 2016 Planned initiation date changed from 1 May 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top